• +1-646-491-9876
    • +91-20-67278686

    Search

    Short Bowel Syndrome-Pipeline Review H1 2017

    Short Bowel Syndrome-Pipeline Review H1 2017

    • Report Code ID: RW0001834375
    • Category Pharmaceuticals
    • No. of Pages 54
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Short Bowel Syndrome - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Short Bowel Syndrome - Pipeline Review, H1 2017, provides an overview of the Short Bowel Syndrome (Gastrointestinal) pipeline landscape.

    Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors and bile-salt binders.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Short Bowel Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Short Bowel Syndrome (Gastrointestinal) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Short Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed and Preclinical stages are 2, 1, 2 and 6 respectively.

    Short Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome (Gastrointestinal) .
    - The pipeline guide reviews pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Short Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Short Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Short Bowel Syndrome (Gastrointestinal) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Short Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Short Bowel Syndrome - Overview
    Short Bowel Syndrome - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Short Bowel Syndrome - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Short Bowel Syndrome - Companies Involved in Therapeutics Development
    Ardelyx Inc
    Hanmi Pharmaceuticals Co Ltd
    Naia Ltd
    Nutrinia Ltd
    OxThera AB
    Sancilio & Company Inc
    Shire Plc
    Tasly Pharmaceutical Group Co Ltd
    Zealand Pharma AS
    Short Bowel Syndrome - Drug Profiles
    exenatide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    glepaglutide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GXG-8 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HM-15910 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    melatonin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NB-1002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NTRA-9620 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Oxabact - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RDX-98940 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SC-403 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    teduglutide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Short Bowel Syndrome - Dormant Projects
    Short Bowel Syndrome - Discontinued Products
    Short Bowel Syndrome - Product Development Milestones
    Featured News & Press Releases
    Feb 06, 2017: Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome
    Dec 19, 2016: IND submission to initiate clinical trials of NB 1001 (XTEN-GLP1) for treatment of Short Bowel Syndrome announced by Naia Rare Diseases
    Nov 29, 2016: Naia Rare Diseases Announces Investigational New Drug Application Submission to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome
    Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
    May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome
    Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016
    Oct 20, 2015: Naia Rare Diseases a subsidiary of Naia, Receives Orphan Drug Designation From U.S. FDA For NB1001 For The Treatment Of Short Bowel Syndrome
    Oct 12, 2015: Naia Successfully Completes Pre-IND Meeting with U.S. FDA for NB1001, Long-Acting GLP-1 Receptor Agonist for Treatment of Short Bowel Syndrome
    Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome
    Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX
    Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan
    Sep 23, 2014: Oxabact Granted EMA Orphan Drug Designation for Treatment of SBS
    Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data
    Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome
    Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Short Bowel Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Short Bowel Syndrome - Pipeline by Ardelyx Inc, H1 2017
    Short Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
    Short Bowel Syndrome - Pipeline by Naia Ltd, H1 2017
    Short Bowel Syndrome - Pipeline by Nutrinia Ltd, H1 2017
    Short Bowel Syndrome - Pipeline by OxThera AB, H1 2017
    Short Bowel Syndrome - Pipeline by Sancilio & Company Inc, H1 2017
    Short Bowel Syndrome - Pipeline by Shire Plc, H1 2017
    Short Bowel Syndrome - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
    Short Bowel Syndrome - Pipeline by Zealand Pharma AS, H1 2017
    Short Bowel Syndrome - Dormant Projects, H1 2017
    Short Bowel Syndrome - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Short Bowel Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Ardelyx Inc
    Hanmi Pharmaceuticals Co Ltd
    Naia Ltd
    Nutrinia Ltd
    OxThera AB
    Sancilio & Company Inc
    Shire Plc
    Tasly Pharmaceutical Group Co Ltd
    Zealand Pharma AS

    Request for Sample

    Report Url http://www.reportsweb.com//short-bowel-syndrome-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//short-bowel-syndrome-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//short-bowel-syndrome-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments